NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/05/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization97.17 mln
Float3.24 mln
Earnings Date05/12/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
0.11
Highly suspicious
1-Year Forecast
115
Transformational upside
Relative Strength
99
/ 100
Top performer
Debt / Equity
0.16
Very low leverage
ROE
-162
Deeply negative
Business Description
Cue Biopharma is a Boston-based company focused on developing injectable medicines that work with the body's immune system to treat cancer and autoimmune diseases. Its most advanced treatments target HPV-related head and neck cancers as well as certain colorectal, gastric, ovarian, and pancreatic cancers, with several programs currently in clinical trials. The company also has earlier-stage treatments in development aimed at reducing harmful immune responses in autoimmune conditions. Cue Biopharma works alongside partners such as LG Chem and Ono Pharmaceutical to advance and commercialize its pipeline.
